CN1761472A - 细胞表面蛋白质的调节 - Google Patents

细胞表面蛋白质的调节 Download PDF

Info

Publication number
CN1761472A
CN1761472A CNA2004800077366A CN200480007736A CN1761472A CN 1761472 A CN1761472 A CN 1761472A CN A2004800077366 A CNA2004800077366 A CN A2004800077366A CN 200480007736 A CN200480007736 A CN 200480007736A CN 1761472 A CN1761472 A CN 1761472A
Authority
CN
China
Prior art keywords
tropomyosin
cell
chemical compound
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800077366A
Other languages
English (en)
Chinese (zh)
Inventor
杰奎琳·多尔比－佩恩
爱德华·欧洛克林
彼得·冈宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Alexandra Hospital for Children
Original Assignee
Royal Alexandra Hospital for Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Alexandra Hospital for Children filed Critical Royal Alexandra Hospital for Children
Publication of CN1761472A publication Critical patent/CN1761472A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/382—Cystic fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
CNA2004800077366A 2003-03-21 2004-03-22 细胞表面蛋白质的调节 Pending CN1761472A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003901316A AU2003901316A0 (en) 2003-03-21 2003-03-21 Regulation of cell surface proteins
AU2003901316 2003-03-21

Publications (1)

Publication Number Publication Date
CN1761472A true CN1761472A (zh) 2006-04-19

Family

ID=31500359

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800077366A Pending CN1761472A (zh) 2003-03-21 2004-03-22 细胞表面蛋白质的调节

Country Status (7)

Country Link
US (1) US20060263781A1 (https=)
EP (1) EP1622626A1 (https=)
JP (1) JP2006524491A (https=)
CN (1) CN1761472A (https=)
AU (1) AU2003901316A0 (https=)
CA (1) CA2517186A1 (https=)
WO (1) WO2004082690A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103228787A (zh) * 2010-09-28 2013-07-31 阿贝拉生物科学公司 用于分泌性蛋白表达的融合蛋白
CN101675339B (zh) * 2007-04-16 2014-04-16 动量制药公司 涉及细胞表面糖基化作用的方法
CN111175431A (zh) * 2020-01-15 2020-05-19 上海林志生物科技有限公司 一种用于肺癌诊断的靶蛋白及其用途、试剂盒
CN113164425A (zh) * 2018-10-30 2021-07-23 佛罗里达大学研究基金会公司 用于治疗囊性纤维化的氨基酸组合物和方法
CN115060898A (zh) * 2021-07-01 2022-09-16 浙江大学 一种检测抗原肌球蛋白1-IgG抗体的试剂盒

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5140218B2 (ja) 2001-09-14 2013-02-06 有限会社コヒーレントテクノロジー 表面洗浄・表面処理に適した帯電アノード水の製造用電解槽及びその製造法、並びに使用方法
CA2468856C (en) 2001-12-05 2011-07-26 Osao Sumita Method and apparatus for producing negative and positive oxidative reductive potential (orp) water
US9168318B2 (en) 2003-12-30 2015-10-27 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and methods of using the same
CA2602522C (en) 2005-03-23 2014-09-09 Oculus Innovative Sciences, Inc. Method of treating skin ulcers using oxidative reductive potential water solution
BRPI0610901B1 (pt) 2005-05-02 2019-04-16 Oculus Innovative Sciences, Inc. Uso de uma solução aquosa de potencial oxi-redutivo (orp).
EP1993571B1 (en) 2006-01-20 2018-07-25 Sonoma Pharmaceuticals, Inc. Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution
WO2010148004A1 (en) 2009-06-15 2010-12-23 Oculus Innovative Sciences, Inc. Solution containing hypochlorous acid and methods of using same

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101675339B (zh) * 2007-04-16 2014-04-16 动量制药公司 涉及细胞表面糖基化作用的方法
CN103228787A (zh) * 2010-09-28 2013-07-31 阿贝拉生物科学公司 用于分泌性蛋白表达的融合蛋白
US9322011B2 (en) 2010-09-28 2016-04-26 Abera Bioscience Ab Fusion protein for secretory protein expression
CN103228787B (zh) * 2010-09-28 2017-06-23 阿贝拉生物科学公司 用于分泌性蛋白表达的融合蛋白
CN113164425A (zh) * 2018-10-30 2021-07-23 佛罗里达大学研究基金会公司 用于治疗囊性纤维化的氨基酸组合物和方法
CN111175431A (zh) * 2020-01-15 2020-05-19 上海林志生物科技有限公司 一种用于肺癌诊断的靶蛋白及其用途、试剂盒
CN115060898A (zh) * 2021-07-01 2022-09-16 浙江大学 一种检测抗原肌球蛋白1-IgG抗体的试剂盒
CN115060898B (zh) * 2021-07-01 2025-08-12 浙江大学 一种检测抗原肌球蛋白1-IgG抗体的试剂盒

Also Published As

Publication number Publication date
US20060263781A1 (en) 2006-11-23
EP1622626A1 (en) 2006-02-08
JP2006524491A (ja) 2006-11-02
AU2003901316A0 (en) 2003-04-03
CA2517186A1 (en) 2004-09-30
WO2004082690A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
CN1310942C (zh) 校正基因
CN1466466A (zh) 心衰治疗剂
CN1768076A (zh) 淀粉样β(1－42)蛋白寡聚体、其衍生物及抗体、其制备方法和用途
CN1675361A (zh) 与人结肠癌相关的基因和多肽
CN1729290A (zh) 在分裂停止后的产多巴胺型神经元前体细胞中特异性表达的基因
CN1761472A (zh) 细胞表面蛋白质的调节
CN1675360A (zh) 与肝细胞癌或结直肠癌相关的基因和多肽
CN1695059A (zh) 诊断结肠癌和胃癌的方法
CN1701078A (zh) 前列腺癌相关基因和多肽
CN1646692A (zh) 在肿瘤中差异表达的基因产物及其用途
CN1444599A (zh) 新型化合物
CN1891825A (zh) 肝细胞癌相关基因和蛋白
CN1231257C (zh) 长pentraxin ptx3用于制备增加雌性动物生殖能力的药物中的用途
CN1705746A (zh) 新转移因子及其应用
CN1684977A (zh) 多肽与编码这些多肽的核酸和它们用于预防、诊断或治疗肝脏失调和上皮癌的用途
CN1609616A (zh) 糖尿病的特异性标记
CN101052718A (zh) 变异型淀粉样蛋白质
CN1720442A (zh) 复制蛋白ciz1
CN1735687A (zh) Mk2相互作用蛋白
CN1633498A (zh) 新型胰岛素/胰岛素样生长因子/松弛素家族多肽及其dna
CN1390256A (zh) 新型蛋白质及其dna
CN1359421A (zh) 新型多肽及其dna
CN1915433A (zh) Annexin A3与癌症的铂类化疗药物耐药性的相关性
CN1170850C (zh) 人血管生成素样蛋白和编码序列及其用途
CN1671843A (zh) 参与转录调控的因子

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication